Scandion Oncology: Amended CORIST phase II part 2 approved - Redeye
Redeye briefly comments on Scandion receiving approval for its amended CORIST phase II part 2 proof-of-concept arm. As previously announced, Scandion is expanding the number of trial sites to assure timely completion in Q2-Q3 2022.
ANNONS
Redeye briefly comments on Scandion receiving approval for its amended CORIST phase II part 2 proof-of-concept arm. As previously announced, Scandion is expanding the number of trial sites to assure timely completion in Q2-Q3 2022.